The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development

Janessa M. Smith, Charles Williams Flexner

Research output: Contribution to journalArticle

Abstract

It is estimated that by 2030 nearly three-quarters of persons living with HIV will be 50 years and older. The aging HIV population presents a new clinical concern for HIV providers: adverse effects from polypharmacy. An aging population means more comorbidities and potentially more drug-drug interactions for providers to manage. This review discusses major comorbidities including cardiovascular disease, anticoagulation, hypertension, diabetes mellitus and malignancy and considerations for drug-interactions with antiretrovirals.

Original languageEnglish (US)
Pages (from-to)S173-S184
JournalAIDS
Volume31
DOIs
StatePublished - Jun 1 2017

Keywords

  • aging
  • antiretroviral therapy
  • drug interactions

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development'. Together they form a unique fingerprint.

  • Cite this